AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2017
Jan 24, 2017
33148_dirs_2017-01-24_d4942c90-505c-4959-a932-8fc921c67f8a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2017-01-23
Reporting Person: Baumgartner Rudolf A (See Remarks)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-23 | Restricted Stock Units | $ | A | 120000 | Acquired | Common Stock (120000) | Direct | |
| 2017-01-23 | Restricted Stock Units | $ | A | 175000 | Acquired | Common Stock (175000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock.
F2: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan") on December 13, 2016 and were amended on January 23, 2017 to modify their vesting schedule. The restricted stock units were modified so that instead of vesting based on the achievement of certain milestones, they will vest in equal annual installments over four years from the December 13, 2016 date of grant, subject to continued service through such dates. The amount in this column does not reflect the decrease in fair value as a result of the modification to the restricted stock units in 2017.
F3: The restricted stock units were issued pursuant to the Plan. The restricted stock units shall vest in equal annual installments over 4 years from the date of grant, subject to continued service through such dates.